Drug resistant tuberculosis at a drug resistant tuberculosis centre, India- Analysis of outcome Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017
Drug resistant tuberculosis in Belarus Source: Eur Respir J 2003; 22: Suppl. 45, 519s Year: 2003
Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Drug resistant tuberculosis in hospitalized patients Source: Eur Respir J 2006; 28: Suppl. 50, 10s Year: 2006
Drug resistance among new TB cases and relapses Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011
Drug resistant tuberculosis: is it enough to justify low treatment success in Russia? Source: Eur Respir J 2001; 18: Suppl. 33, 175s Year: 2001
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Drug resistance in previously treated patients of tuberculosis in pre DOTS and DOTS era and its implications Source: Annual Congress 2009 - Tuberculosis control Year: 2009
Drug resistance pattern of directly observed treatment shortcourse (DOTS) category-II relapse patients Source: Annual Congress 2011 - Tuberculosis epidemiology and public health Year: 2011
Outcomes of individualized treatment for MDR TB in Iran Source: Annual Congress 2007 - Medical and surgical treatment of susceptible and resistant tuberculosis Year: 2007
Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Drug resistance pattern & response to supervised chemotherapy of drug resistant pulmonary tuberculosis - a study of hospitalized cases from tuberculosis diseases treatment centre Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003
Antituberculosis drug resistance rates in patients newly diagnosed with TB in Istanbul Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012
Drug resistance in tuberculosis Source: Eur Respir J 2005; 25: 376-379 Year: 2005
Drug resistant pattern of antitubercular drugs in India Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008
Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Effectiveness of national standardized and WHO regimens and risk factors of unfavorable outcomes in treatment of patients with MDR-TB in Novosibirsk Oblast, Russian Federation Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014
Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013